GlobeNewswire: Vineti Contains the last 10 of 31 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:07:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/03/23/2408599/0/en/Vineti-secures-new-patent-from-USPTO-for-individualized-medicine-platform.html?f=22&fvtc=4&fvtv=35107Vineti secures new patent from USPTO for individualized medicine platform2022-03-23T13:00:00Z<![CDATA[SAN FRANCISCO, March 23, 2022 (GLOBE NEWSWIRE) -- Vineti, Inc., the provider of the leading digital platform of record for cell and gene therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,271,741, which is directed to an individualized medicine platform. The new U.S. patent further cements Vineti’s lead in enterprise platform technology for personalized therapeutics.]]>https://www.globenewswire.com/news-release/2022/03/04/2397211/0/en/Vineti-Appoints-Ann-Klein-as-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=35107Vineti Appoints Ann Klein as Chief Executive Officer2022-03-04T15:00:00Z<![CDATA[SAN FRANCISCO, March 04, 2022 (GLOBE NEWSWIRE) -- Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics, today announced the appointment of Ann Klein as Chief Executive Officer (CEO) and board member. Ms. Klein brings more than 25 years of healthcare technology product strategy, management, sales and marketing experience as Vineti extends its Personalized Therapy Management® (PTM) platform and transitions into its next phase of growth. Ms. Klein succeeds Vineti Co-founder Amy DuRoss, who will continue to advise the company.]]>https://www.globenewswire.com/news-release/2022/01/26/2373542/0/en/Vineti-achieves-SOC2-Type-II-compliance.html?f=22&fvtc=4&fvtv=35107Vineti achieves SOC2 Type II compliance2022-01-26T14:00:00Z<![CDATA[SAN FRANCISCO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics, today announced the successful completion of its Service Organization Control (SOC®) 2 Type II audit.]]>https://www.globenewswire.com/news-release/2022/01/10/2364086/0/en/Vineti-introduces-new-PTM-Integration-Suite-purpose-built-connectivity-and-interoperability-for-cell-and-gene-therapies.html?f=22&fvtc=4&fvtv=35107Vineti introduces new PTM® Integration Suite: purpose-built connectivity and interoperability for cell and gene therapies2022-01-10T14:00:00Z<![CDATA[SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy Management® (PTM) solution. This API-based PTM® Integration Suite delivers purpose-built connectivity for orchestrating cell and gene therapy systems, ultimately speeding and simplifying workflows and providing better care for patients..]]>https://www.globenewswire.com/news-release/2021/12/08/2348129/0/en/Be-The-Match-BioTherapies-and-Vineti-collaborate-to-develop-innovative-integrated-supply-chain-management-solutions-for-cell-and-gene-therapies.html?f=22&fvtc=4&fvtv=35107Be The Match BioTherapies® and Vineti collaborate to develop innovative, integrated supply chain management solutions for cell and gene therapies2021-12-08T11:30:00Z<![CDATA[MINNEAPOLIS and SAN FRANCISCO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies (CGTs), and Vineti, the provider of the leading digital enterprise platform for cell and gene therapy supply chains, today announced a collaboration to develop joint solutions that simplify and scale supply chain management of cell and gene therapies.]]>https://www.globenewswire.com/news-release/2021/10/19/2316254/0/en/Autolomous-and-Vineti-form-strategic-partnership-to-deliver-end-to-end-supply-chain-management-solutions-for-cell-and-gene-therapy-sector.html?f=22&fvtc=4&fvtv=35107Autolomous and Vineti form strategic partnership to deliver end to end supply chain management solutions for cell and gene therapy sector2021-10-19T10:00:00Z<![CDATA[LONDON and SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, and Vineti, a provider of leading digital enterprise platforms for cell and gene therapy supply chains, today announce a non-exclusive collaborative partnership.]]>https://www.globenewswire.com/news-release/2021/10/12/2312176/0/en/K%C3%B6rber-and-Vineti-Announce-Partnership-to-Provide-Improved-Manufacturing-Performance-and-Visibility-Globally-for-Cell-and-Gene-Based-Therapies.html?f=22&fvtc=4&fvtv=35107Körber and Vineti Announce Partnership to Provide Improved Manufacturing Performance and Visibility Globally for Cell and Gene-Based Therapies2021-10-12T07:05:00Z<![CDATA[LÜNEBURG, Germany and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Körber, the leading MES supplier for pharma and biotech, and Vineti, the world’s only enterprise software platform supporting supply chain orchestration for clinical and commercial cell and gene therapies, today announced a partnership to integrate Werum PAS-X MES with Vineti’s industry-leading Personalized Therapy Management® (PTM) platform. The partnership will empower biopharma customers with an integrated PAS-X MES and supply chain and data management solution to bring life-saving cell and gene-based therapies to patients in need.]]>https://www.globenewswire.com/news-release/2021/08/12/2279866/0/en/Lykan-Bioscience-and-Vineti-Announce-Partnership-to-Advance-Cell-based-Therapies-from-Clinical-to-Commercialization.html?f=22&fvtc=4&fvtv=35107Lykan Bioscience and Vineti Announce Partnership to Advance Cell-based Therapies from Clinical to Commercialization2021-08-12T13:00:00Z<![CDATA[Lykan Bioscience’s world-class manufacturing capabilities, integrated with Vineti’s leading digital enterprise platform for cell and gene therapy supply chains, will streamline process development and manufacturing to deliver these therapies to patients in need Lykan Bioscience’s world-class manufacturing capabilities, integrated with Vineti’s leading digital enterprise platform for cell and gene therapy supply chains, will streamline process development and manufacturing to deliver these therapies to patients in need]]>https://www.globenewswire.com/news-release/2021/08/10/2277802/0/en/Vineti-announces-agreement-with-Imvax-to-utilize-Vineti-s-PTM-Essentials-solution.html?f=22&fvtc=4&fvtv=35107Vineti announces agreement with Imvax to utilize Vineti's PTM Essentials™ solution2021-08-10T11:00:00Z<![CDATA[Vineti’s enterprise technology will enable critical patient-specific Chain of Custody management for Imvax, supporting Imvax’s goal of reaching more patients as fast as possible Vineti’s enterprise technology will enable critical patient-specific Chain of Custody management for Imvax, supporting Imvax’s goal of reaching more patients as fast as possible]]>https://www.globenewswire.com/news-release/2021/05/26/2236056/0/en/Ori-Biotech-and-Vineti-Form-Strategic-Partnership-to-Deliver-Integrated-Manufacturing-and-Supply-Chain-Solutions-for-Cell-and-Gene-Therapies.html?f=22&fvtc=4&fvtv=35107Ori Biotech and Vineti Form Strategic Partnership to Deliver Integrated Manufacturing and Supply Chain Solutions for Cell and Gene Therapies2021-05-26T07:05:00Z<![CDATA[Platform integration will provide therapy developers with full end-to-end visibility, control, and insights into manufacturing and supply chain Platform integration will provide therapy developers with full end-to-end visibility, control, and insights into manufacturing and supply chain]]>